RESUMO
The weakness is one of the negative factors that degrade cancer patients' quality of life. The nature of weakness may be multifactorial but among mechanisms of development of weakness a syndrome of chronic inflammation plays a crucial role. Therapy aimed at reducing of inflammation degree allows correcting other cancer-related symptoms and improving the quality of life of incurable patients.
Assuntos
Neoplasias Inflamatórias Mamárias/fisiopatologia , Debilidade Muscular/fisiopatologia , Adulto , Idoso , Feminino , Humanos , Inflamação/metabolismo , Inflamação/patologia , Inflamação/fisiopatologia , Inflamação/terapia , Neoplasias Inflamatórias Mamárias/metabolismo , Neoplasias Inflamatórias Mamárias/patologia , Neoplasias Inflamatórias Mamárias/terapia , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/metabolismo , Debilidade Muscular/patologia , Debilidade Muscular/terapiaRESUMO
In this work there is considered the possibility of correction of therapy for weakness syndrome in incurable patients with the use of drugs affecting dopamine and serotonin exchanges. It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy.